Form 4: Lexicon Pharmaceuticals Executive Wendy McDermott Reports Stock Option and Restricted Stock Unit Grants

Wendy McDermott, SVP of Human Resources at Lexicon Pharmaceuticals, reports the acquisition of stock options and restricted stock units.

Summary

• Wendy McDermott, SVP of Human Resources at Lexicon Pharmaceuticals, filed a Form 4 on February 18, 2025.
• The report details the grant of stock options and restricted stock units.
• McDermott was granted options to purchase 649,780 shares of common stock at an exercise price of $0.695 on February 13, 2025.
• These options vest over time, with 25% vesting on the first anniversary of the grant and the remainder vesting monthly over the following 36 months.
• McDermott also received 433,180 restricted stock units (RSUs) on February 13, 2025.
• These RSUs vest in three equal installments on February 28 of each of the three years following the year of grant.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to executive compensation, and does not inherently convey positive or negative sentiment.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

This filing is a routine disclosure of executive compensation in the form of stock options and restricted stock units, which is a common practice in the pharmaceutical industry to incentivize and retain key personnel.

Stakeholder Impact

• The grant of stock options and restricted stock units may incentivize the executive to improve company performance, potentially benefiting shareholders.
• The vesting schedule of the equity awards aligns the executive's interests with the long-term success of the company.

Key Dates